|
1
|
Braganza MZ, Kitahara CM, Berrington de
González A, Inskip PD, Johnson KJ and Rajaraman P: Ionizing
radiation and the risk of brain and central nervous system tumors:
A systematic review. Neuro-oncol. 14:1316–1324. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gonzalez J and Gilbert MR: Treatment of
astrocytomas. Curr Opin Neurol. 18:632–638. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hentschel SJ and Lang FF: Current surgical
management of glioblastoma. Cancer J. 9:113–125. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wallner KE, Galicich JH, Krol G, Arbit E
and Malkin MG: Patterns of failure following treatment for
glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat
Oncol Biol Phys. 16:1405–1409. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sneed PK, Gutin PH, Larson DA, Malec MK,
Phillips TL, Prados MD, Scharfen CO, Weaver KA and Wara WM:
Patterns of recurrence of glioblastoma multiforme after external
irradiation followed by implant boost. Int J Radiat Oncol Biol
Phys. 29:719–727. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Aydin H, Sillenberg I and von Lieven H:
Patterns of failure following CT-based 3-D irradiation for
malignant glioma. Strahlenther Onkol. 177:424–431. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim SS, Pirollo KF and Chang EH: Isolation
and culturing of glioma cancer stem cells. Curr Protoc Cell Biol.
23.10.1–23.10.10. 2015. View Article : Google Scholar
|
|
9
|
Lathia JD, Mack SC, Mulkearns-Hubert EE,
Valentim CL and Rich JN: Cancer stem cells in glioblastoma. Genes
Dev. 29:1203–1217. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang H and Li SY: Research progression of
CD133 as a marker of cancer stem cells. Clin J Cancer. 29:243–247.
2010.
|
|
11
|
Zeppernick F, Ahmadi R, Campos B, Dictus
C, Helmke BM, Becker N, Lichter P, Unterberg A, Radlwimmer B and
Herold-Mende CC: Stem cell marker CD133 affects clinical outcome in
glioma patients. Clin Cancer Res. 14:123–129. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Auffinger B, Tobias AL, Han Y, Lee G, Guo
D, Dey M, Lesniak MS and Ahmed AU: Conversion of differentiated
cancer cells into cancer stem-like cells in a glioblastoma model
after primary chemotherapy. Cell Death Differ. 21:1119–1131. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jeon YK, Kim SH, Choi SH, Kim KH, Yoo BC,
Ku JL and Park JG: Promoter hypermethylation and loss of CD133 gene
expression in colorectal cancers. World J Gastroenterol.
16:3153–3160. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Min KJ, So KA, Ouh YT, Hong JH and Lee JK:
The effects of DNA methylation and epigenetic factors on the
expression of CD133 in ovarian cancers. J Ovarian Res. 5:282012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gopisetty G, Xu J, Sampath D, Colman H and
Puduvalli VK: Epigenetic regulation of CD133/PROM1 expression in
glioma stem cells by Sp1/myc and promoter methylation. Oncogene.
32:3119–3129. 2013. View Article : Google Scholar
|
|
16
|
Shmelkov SV, Jun L, St Clair R, McGarrigle
D, Derderian CA, Usenko JK, Costa C, Zhang F, Guo X and Rafii S:
Alternative promoters regulate transcription of the gene that
encodes stem cell surface protein AC133. Blood. 103:2055–2061.
2004. View Article : Google Scholar
|
|
17
|
Tabu K, Sasai K, Kimura T, Wang L,
Aoyanagi E, Kohsaka S, Tanino M, Nishihara H and Tanaka S: Promoter
hypomethylation regulates CD133 expression in human gliomas. Cell
Res. 18:1037–1046. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shi J, Shi W, Ni L, Xu X, Su X, Xia L, Xu
F, Chen J and Zhu J: OCT4 is epigenetically regulated by DNA
hypomethylation of promoter and exon in primary gliomas. Oncol Rep.
30:201–206. 2013.PubMed/NCBI
|
|
19
|
Bigner SH, Matthews MR, Rasheed BK,
Wiltshire RN, Friedman HS, Friedman AH, Stenzel TT, Dawes DM,
McLendon RE and Bigner DD: Molecular genetic aspects of
oligodendrogliomas including analysis by comparative genomic
hybridization. Am J Pathol. 155:375–386. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jansen GA, Mihalik SJ, Watkins PA, Moser
HW, Jakobs C, Denis S and Wanders RJ: Phytanoyl-CoA hydroxylase is
present in human liver, located in peroxisomes, and deficient in
Zellweger syndrome: Direct, unequivocal evidence for the new,
revised pathway of phytanic acid alpha-oxidation in humans. Biochem
Biophys Res Commun. 229:205–210. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Germano I, Swiss V and Casaccia P: Primary
brain tumors, neural stem cell, and brain tumor cancer cells: Where
is the link? Neuropharmacology. 58:903–910. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
He H, Li MW and Niu CS: The pathological
characteristics of glioma stem cell niches. J Clin Neurosci.
19:121–127. 2012. View Article : Google Scholar
|
|
23
|
Achanta P, Sedora Roman NI and
Quiñones-Hinojosa A: Gliomagenesis and the use of neural stem cells
in brain tumor treatment. Anticancer Agents Med Chem. 10:121–130.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schwab LP, Peacock DL, Majumdar D, Ingels
JF, Jensen LC, Smith KD, Cushing RC and Seagroves TN:
Hypoxia-inducible factor 1α promotes primary tumor growth and
tumor-initiating cell activity in breast cancer. Breast Cancer Res.
14:R62012. View
Article : Google Scholar
|
|
25
|
Chakraborty S, Kanakasabai S and Bright
JJ: Constitutive androstane receptor agonist CITCO inhibits growth
and expansion of brain tumour stem cells. Br J Cancer. 104:448–459.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kahlert UD, Maciaczyk D, Dai F, Claus R,
Firat E, Doostkam S, Bogiel T, Carro MS, Döbrössy M, Herold-Mende
C, et al: Resistance to hypoxia-induced, BNIP3-mediated cell death
contributes to an increase in a CD133-positive cell population in
human glioblastomas in vitro. J Neuropathol Exp Neurol.
71:1086–1099. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu G, Yuan X, Zeng Z, Tunici P, Ng H,
Abdulkadir IR, Lu L, Irvin D, Black KL and Yu JS: Analysis of gene
expression and chemoresistance of CD133+ cancer stem
cells in glioblastoma. Mol Cancer. 5:672006. View Article : Google Scholar
|
|
28
|
Liu JM, Mao BY, Hong S, Liu YH and Wang
XJ: The postoperative brain tumour stem cell (BTSC) niche and
cancer recurrence. Adv Ther. 25:389–398. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gómez-Díaz E, Jordà M, Peinado MA and
Rivero A: Epigenetics of host-pathogen interactions: The road ahead
and the road behind. PLoS Pathog. 8:e10030072012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Baba T, Convery PA, Matsumura N, Whitaker
RS, Kondoh E, Perry T, Huang Z, Bentley RC, Mori S, Fujii S, et al:
Epigenetic regulation of CD133 and tumorigenicity of
CD133+ ovarian cancer cells. Oncogene. 28:209–218. 2009.
View Article : Google Scholar
|
|
31
|
He J, Shan Z, Li L, Liu F, Liu Z, Song M
and Zhu H: Expression of glioma stem cell marker CD133 and
O6-methylguanine-DNA methyltransferase is associated with
resistance to radiotherapy in gliomas. Oncol Rep. 26:1305–1313.
2011.PubMed/NCBI
|
|
32
|
Mudbhary R, Hoshida Y, Chernyavskaya Y,
Jacob V, Villanueva A, Fiel MI, Chen X, Kojima K, Thung S, Bronson
RT, et al: UHRF1 overexpression drives DNA hypomethylation and
hepatocellular carcinoma. Cancer Cell. 25:196–209. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hackett JA and Surani MA: DNA methylation
dynamics during the mammalian life cycle. Philos Trans R Soc Lond B
Biol Sci. 368:201103282013. View Article : Google Scholar :
|
|
34
|
Krutovskikh V and Partensky C: New
insights in oncology: Epigenetics and cancer stem cells. Cancer
Radiother. 15:716–722. 2011.In French. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Radpour R, Barekati Z, Kohler C,
Schumacher MM, Grussenmeyer T, Jenoe P, Hartmann N, Moes S, Letzkus
M, Bitzer J, et al: Integrated epigenetics of human breast cancer:
Synoptic investigation of targeted genes, microRNAs and proteins
upon demethylation treatment. PLoS One. 6:e273552011. View Article : Google Scholar : PubMed/NCBI
|
